EP1064022A4 - Peptides de liaison de hla et leurs applications - Google Patents

Peptides de liaison de hla et leurs applications

Info

Publication number
EP1064022A4
EP1064022A4 EP98910404A EP98910404A EP1064022A4 EP 1064022 A4 EP1064022 A4 EP 1064022A4 EP 98910404 A EP98910404 A EP 98910404A EP 98910404 A EP98910404 A EP 98910404A EP 1064022 A4 EP1064022 A4 EP 1064022A4
Authority
EP
European Patent Office
Prior art keywords
applications
binding peptides
hla binding
hla
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98910404A
Other languages
German (de)
English (en)
Other versions
EP1064022A1 (fr
Inventor
Alessandro Sette
Ralph T Kubo
John Sidney
Esteban Celis
Howard M Grey
Scott Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of EP1064022A1 publication Critical patent/EP1064022A1/fr
Publication of EP1064022A4 publication Critical patent/EP1064022A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP98910404A 1998-03-13 1998-03-13 Peptides de liaison de hla et leurs applications Withdrawn EP1064022A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/005039 WO1999045954A1 (fr) 1998-03-13 1998-03-13 Peptides de liaison de hla et leurs applications

Publications (2)

Publication Number Publication Date
EP1064022A1 EP1064022A1 (fr) 2001-01-03
EP1064022A4 true EP1064022A4 (fr) 2004-09-29

Family

ID=22266589

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98910404A Withdrawn EP1064022A4 (fr) 1998-03-13 1998-03-13 Peptides de liaison de hla et leurs applications

Country Status (5)

Country Link
EP (1) EP1064022A4 (fr)
JP (1) JP2002507397A (fr)
AU (1) AU6465598A (fr)
CA (1) CA2323632A1 (fr)
WO (1) WO1999045954A1 (fr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6407063B1 (en) 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
WO2000020445A2 (fr) 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Antigenes tumoraux et clones de lymphocyte t cytotoxique (ctl) isoles grace a un nouveau procede
US6541214B1 (en) * 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
GB9826143D0 (en) * 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
EP1136555A4 (fr) * 1998-12-01 2002-11-27 Kyogo Itoh Nouvelle proteine d'antigene tumoral art-1 et peptide d'antigene tumoral de cette derniere
IT1309584B1 (it) * 1999-02-26 2002-01-24 San Raffaele Centro Fond Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso.
AU1440601A (en) * 1999-10-29 2001-05-14 Argonex Pharmaceuticals, Inc. Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma
WO2001036452A2 (fr) * 1999-11-18 2001-05-25 Epimmune Inc. Analogues heteroclites et procedes associes
AU2087401A (en) * 1999-12-10 2001-06-18 Epimmune, Inc. Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
JP2003517310A (ja) * 1999-12-10 2003-05-27 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、ｍａｇｅ２／３に対する細胞性免疫応答の誘導
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
WO2001041788A1 (fr) * 1999-12-10 2001-06-14 Epimmune, Inc. Declenchement de reponses immunitaires cellulaires contre p53 au moyen de compositions d'acides nucleiques et de peptides
CA2394741A1 (fr) * 1999-12-21 2001-06-28 Epimmune Inc. Induction de reponses immunitaires cellulaires aux antigenes du cancer de la prostate au moyen de compositions de peptides et d'acides nucleiques
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
FR2806727A1 (fr) * 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
AU2001253029A1 (en) * 2000-03-30 2001-10-15 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
CN1107681C (zh) * 2000-08-11 2003-05-07 中国科学院微生物研究所 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用
PL365789A1 (pl) * 2000-08-14 2005-01-10 Corixa Corporation Kompozycje oraz sposoby leczenia i diagnozowania nowotworów związanych z Her-2/neu
JP2004508340A (ja) * 2000-09-01 2004-03-18 エピミューン　インコーポレーティッド Ｈｌａ結合ペプチドおよびその使用方法
EP1195381A1 (fr) 2000-09-28 2002-04-10 Immusystems GmbH Epitopes du virus de l'hépatite C spécifiques à des lymphocytes T de type CD4+
EP1404841B1 (fr) 2000-10-31 2011-08-17 Eisai Inc. Acide nucleique de cyp1b1 et ses procedes d'utilisation
JP2004535369A (ja) * 2001-03-01 2004-11-25 アメリカ合衆国 試薬およびワクチンとして使用するための免疫原性ｈｉｖペプチド
JP2005505242A (ja) * 2001-03-07 2005-02-24 マンカインド コーポレイション 癌用抗新生血管系調製物
WO2003008537A2 (fr) * 2001-04-06 2003-01-30 Mannkind Corporation Sequences d'epitope
EP1752160A3 (fr) * 2001-04-06 2007-05-30 Mannkind Corporation Sequences d'epitopes
AU2002305138A1 (en) 2001-04-09 2002-10-21 Mayo Foundation For Medical Education And Research Methods and materials for cancer treatment
AU2002322009A1 (en) 2001-05-18 2002-12-03 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
US7223836B2 (en) 2001-06-05 2007-05-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Peptides for chlamydophila pneumoniae vaccine and diagnosis
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
CA2357906A1 (fr) * 2001-09-28 2003-03-28 Institut Pasteur Identification de nouveaux epitopes de cd8 de proteines ayant des proprietes therapeutiques et immunologiques pour lutter contre les infections a vih
DE60238864D1 (de) 2001-11-07 2011-02-17 Mankind Corp Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
JP4035845B2 (ja) * 2001-12-10 2008-01-23 株式会社グリーンペプタイド 腫瘍抗原
EP1495322A4 (fr) * 2002-04-05 2006-09-06 Epimmune Inc Analogues heteroclitiques et procedes associes
CA2514419A1 (fr) 2003-01-28 2004-08-12 Proscan Rx Pharma Inc. Diagnostic et traitement du cancer de la prostate
JPWO2005007694A1 (ja) * 2003-07-16 2007-09-20 株式会社グリーンペプタイド ＨＥＲ２／ｎｅｕペプチドおよびその治療上の用途
EP1670509A4 (fr) * 2003-09-03 2007-10-31 Dendritherapeutics Inc Vaccins multiplex
US7488793B2 (en) * 2003-09-22 2009-02-10 Ludwig Institute For Cancer Research Isolated peptide which binds to HLA-Cw*07 and uses thereof
KR20060087574A (ko) * 2003-09-22 2006-08-02 가부시키가이샤 그린 펩티드 Ｃ형 간염 바이러스 유래 펩티드
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
EP1759323A2 (fr) 2004-04-21 2007-03-07 AlgoNomics N.V. Methode ed marquage par affinite de complexes de peptides/proteines
CN1954068B (zh) * 2004-04-30 2011-03-02 日本电气株式会社 Hla-结合肽，其前体，编码这些肽序列的dna片段和重组载体
WO2006035681A1 (fr) * 2004-09-27 2006-04-06 National University Corporation Tokyo Medical And Dental University EPITOPES ANTITUMORAUX Tax RESTREINTS EN HLA-A11
JP5116150B2 (ja) * 2005-09-07 2013-01-09 日本電気株式会社 Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター
US8378072B2 (en) 2006-04-13 2013-02-19 Declion Pharmaceuticals, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
WO2008010010A1 (fr) * 2006-07-12 2008-01-24 Vaxon Biotech Identification, optimisation et utilisation d'épitopes cryptiques hla-b7 en immunothérapie
WO2009051797A1 (fr) 2007-10-16 2009-04-23 Peptimmune, Inc. Procédés de conception et de préparation de vaccins comprenant des compositions de polymères à séquences dirigées via l'expansion dirigée d'épitopes
CN101969991A (zh) * 2008-01-18 2011-02-09 Aeras全球Tb疫苗基金会 可诱导细胞介导免疫的疟疾疫苗组合物和组分
WO2010086294A2 (fr) 2009-01-28 2010-08-05 Epimmune Inc. Polypeptides de liaison de pan-dr et leurs utilisations
EP2482834A4 (fr) * 2009-09-30 2013-07-10 Univ Saint Louis Peptides déclenchant des réponses hétéro sous-typiques des lymphocytes t contre la grippe
US20130183376A1 (en) 2010-09-08 2013-07-18 Saitama Medical University Hepatitis c virus liposome vaccine
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
CN102286075A (zh) * 2011-08-01 2011-12-21 中国人民解放军第三军医大学 乙肝病毒表面抗原的免疫显性hla-a*1101限制性ctl表位及其应用
US9517252B2 (en) 2011-09-09 2016-12-13 Agency For Science, Technology And Research p53 activating peptides
BR112014017819B1 (pt) * 2012-01-20 2024-01-09 Fernando Thomé Kreutz Método de produzir células cancerígenas imunogênicas isoladas
JP5999703B2 (ja) * 2013-01-09 2016-09-28 国立大学法人 東京医科歯科大学 ＨＬＡ−ＤＲ１拘束性Ｔａｘ特異的ＣＤ４＋Ｔ細胞エピトープ
MY187178A (en) * 2015-02-18 2021-09-08 Hoffmann La Roche Immunoconjugates for specific induction of t cell cytotoxicity against a target cell
CN105037559B (zh) * 2015-08-17 2018-09-25 北京康爱瑞浩生物科技股份有限公司 治疗或预防乙肝的细胞毒性t淋巴细胞及其制备方法
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
TWI796642B (zh) 2015-08-28 2023-03-21 德商英麥提克生物技術股份有限公司 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
JP2020515283A (ja) 2016-12-28 2020-05-28 インブバックス，インコーポレーテッド インフルエンザワクチン
CN111655280B (zh) * 2017-09-01 2025-01-14 达纳-法伯癌症研究所股份有限公司 用于治疗癌症的bcma和taci抗原特异的免疫原性肽
EP3545967A1 (fr) * 2018-03-28 2019-10-02 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Plate-forme d'immunisation contre le cancer
US12247053B2 (en) 2018-10-26 2025-03-11 Saint Louis University Peptides for inducing heterosubtypic influenza T cell responses
EP3908591A4 (fr) * 2019-01-11 2023-01-25 Agency for Science, Technology and Research Utilisation de peptides du virus de l'hépatite b (vhb) restreints par hla-a*11 : 01 permettant d'identifier des lymphocytes t cd8+ spécifiques du vhb
BR112021017404A2 (pt) * 2019-03-04 2022-02-01 Univ Health Network Receptores de células t e métodos de uso dos mesmos
CN113795583B (zh) 2019-03-04 2026-03-27 大学健康网络 T细胞受体及其使用方法
MX2021010541A (es) 2019-03-04 2021-12-15 Univ Health Network Receptores de linfocitos t y metodos de uso de estos.
WO2020178744A1 (fr) 2019-03-04 2020-09-10 University Health Network Récepteurs de lymphocytes t et leurs procédés d'utilisation
US12448429B2 (en) 2019-03-06 2025-10-21 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
SG11202109701SA (en) 2019-03-25 2021-10-28 Univ Health Network T cell receptors and methods of use thereof
CN115974985A (zh) * 2019-12-13 2023-04-18 南京大户生物科技有限公司 乙型肝炎病毒抗原的胸腺依赖性淋巴细胞抗原表位肽及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003205A1 (fr) * 1992-08-07 1994-02-17 Cytel Corporation Peptides de liaison de hla, et leurs utilisations
WO1997033602A1 (fr) * 1996-03-11 1997-09-18 Cytel Corporation Peptides presentant une affinite accrue de liaison avec des molecules
WO1997034617A1 (fr) * 1996-03-21 1997-09-25 Cytel Corporation Peptides de liaison aux hla et utilisations
WO1997034621A1 (fr) * 1996-03-21 1997-09-25 Cytel Corporation Peptides de fixation de hla-a2.1 et leurs utilisations
WO1998032456A1 (fr) * 1997-01-23 1998-07-30 Epimmune, Inc. Identification d'epitopes a restriction dr largement reactifs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003205A1 (fr) * 1992-08-07 1994-02-17 Cytel Corporation Peptides de liaison de hla, et leurs utilisations
WO1997033602A1 (fr) * 1996-03-11 1997-09-18 Cytel Corporation Peptides presentant une affinite accrue de liaison avec des molecules
WO1997034617A1 (fr) * 1996-03-21 1997-09-25 Cytel Corporation Peptides de liaison aux hla et utilisations
WO1997034621A1 (fr) * 1996-03-21 1997-09-25 Cytel Corporation Peptides de fixation de hla-a2.1 et leurs utilisations
WO1998032456A1 (fr) * 1997-01-23 1998-07-30 Epimmune, Inc. Identification d'epitopes a restriction dr largement reactifs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALTUVIA YAEL ET AL: "A structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets", HUMAN IMMUNOLOGY, vol. 58, no. 1, November 1997 (1997-11-01), pages 1 - 11, XP002279422, ISSN: 0198-8859 *
GREY H M ET AL: "CLASS I MHC-PEPTIDE INTERACTIONS: STRUCTURAL REQUIREMENTS AND FUNCTIONAL IMPLICATIONS", CANCER SURVEYS, OXFORD, GB, vol. 22, 1995, pages 37 - 49, XP008024840 *
PARTIDOS C D ET AL: "Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides", IMMUNOLOGY, vol. 87, no. 2, 1996, pages 179 - 185, XP002279421, ISSN: 0019-2805 *
See also references of WO9945954A1 *

Also Published As

Publication number Publication date
JP2002507397A (ja) 2002-03-12
AU6465598A (en) 1999-09-27
WO1999045954A1 (fr) 1999-09-16
CA2323632A1 (fr) 1999-09-16
EP1064022A1 (fr) 2001-01-03

Similar Documents

Publication Publication Date Title
ATA898A (de) Snowboard - einstiegsbindung
EE05538B1 (et) Interleukiin-18 seostuvad valgud, nende valmistamine ja kasutamine
DE69827307D1 (de) Turbolader
DE69808854D1 (de) Buchbindevorrichtung
EP0888120A4 (fr) Peptides de liaison aux hla et utilisations
DE69828963D1 (de) Wirstoffabgabe und gentherapiesystem
DE69611955D1 (de) Bindeelement
DE59809278D1 (de) Hysteresebremse
DE69833154D1 (de) Mikrovorrichtung
NO20002387D0 (no) FremgangsmÕter og systemer ved applikasjonsomslag
EP1263775A4 (fr) Peptides de liaison hla et utilisations de ces derniers
DE59706609D1 (de) Spannstock
EP0879283A4 (fr) Genes de glutenine et leurs utilisations
DE59703056D1 (de) Spannstock
DK0865832T3 (da) Sorteringssystem
DE69706521D1 (de) Modifiziertes inulin
DE69610791D1 (de) Bindevorrichtung
TR199701666A3 (tr) Sismanliga karsi proteinler
KR960010685A (ko) 펩티드 및 그 용도
DE69827522D1 (de) Bindevorrichtung
DE69811185D1 (de) Ordner
DE69506405D1 (de) Bindevorrichtung
FR2720748B1 (fr) Protéines du complexe BTF2 et leurs applications.
DE59802215D1 (de) Bindevorrichtung
EP1313505A4 (fr) Peptides de fixation de hla et leurs utilisations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000929

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EPIMMUNE INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/82 B

Ipc: 7C 07K 14/02 B

Ipc: 7C 07K 7/00 B

Ipc: 7A 61K 39/00 B

Ipc: 7A 61K 39/29 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040813

17Q First examination report despatched

Effective date: 20070820

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080401